Efficacy of Vonoprazan Based Dual and Triple Therapy for Patient With Helicobacter Pylori Infection
NCT ID: NCT07045688
Last Updated: 2025-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
150 participants
INTERVENTIONAL
2025-05-13
2025-11-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vonoprazan-based Therapy Versus Standard Regimen for Helicobacter Pylori Infection Management
NCT05614934
7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication
NCT06576882
Efficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication
NCT05469685
Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori
NCT05649540
Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial
NCT07068607
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Efficacy of Vonoprazan based dual therapy for naive patient with Helicobacter Pylori infection
we assess the efficacy of Vonoprazan based dual therapy for eradication of Helicobacter Pylori infection in naive patient.
Efficacy of Vonoprazan based dual therapy for naive patient with Helicobacter Pylori infection
we assess the efficacy of Vonoprazan based dual therapy for eradication of Helicobacter Pylori infection in naive patient.
Efficacy of Vonoprazan based triple therapy for naive patient with Helicobacter Pylori infection
we assess the efficacy of Vonoprazan based triple therapy for eradication of Helicobacter Pylori infection in naive patient.
Efficacy of Vonoprazan based triple therapy for naive patient with Helicobacter Pylori infection
we assess the efficacy of Vonoprazan based triple therapy for eradication of Helicobacter Pylori infection in naive patient.
Efficacy of PPI based triple therapy for naive patient with Helicobacter Pylori infection
we assess the efficacy of proton pump inhibitors (PPI) based dual therapy for eradication of Helicobacter Pylori infection in naive patient.
Efficacy of PPI based triple therapy for naive patient with Helicobacter Pylori infection
we assess the efficacy of PPI based triple therapy for eradication of Helicobacter Pylori infection in naive patient.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Efficacy of Vonoprazan based dual therapy for naive patient with Helicobacter Pylori infection
we assess the efficacy of Vonoprazan based dual therapy for eradication of Helicobacter Pylori infection in naive patient.
Efficacy of Vonoprazan based triple therapy for naive patient with Helicobacter Pylori infection
we assess the efficacy of Vonoprazan based triple therapy for eradication of Helicobacter Pylori infection in naive patient.
Efficacy of PPI based triple therapy for naive patient with Helicobacter Pylori infection
we assess the efficacy of PPI based triple therapy for eradication of Helicobacter Pylori infection in naive patient.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* H. pylori infection: Confirmed by histopathology or non-invasive tests (e.g., stool antigen test).
Exclusion Criteria
* Allergies: Known allergies to study medications or components.
* Patients cannot finish treatment course.
* Patient missed follow up.
* Patients refusing or neglecting test of cure for H. pylori.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrew Kamil Wadie
Resident,Internal Medicine Departement , Faculty of Medicine Sohag university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag University Hospital
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Hamdy S Mohammed, Professor
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Magdy M Amin, Professor
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017 Feb;112(2):212-239. doi: 10.1038/ajg.2016.563. Epub 2017 Jan 10.
Argueta EA, Alsamman MA, Moss SF, D'Agata EMC. Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter pylori in a US Population. Gastroenterology. 2021 May;160(6):2181-2183.e1. doi: 10.1053/j.gastro.2021.02.014. Epub 2021 Feb 9. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med--25-5-10MS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.